OncClub

Yasir Y. Elamin, MD, discusses findings from a phase 2 study (NCT03066206), which found that poziotinib induced an investigator-assessed overall response rate of 32% in patients with non–small cell lung cancer harboring EGFR exon 20 mutations.

Matthew H. G. Katz, MD, sheds light on the phase 2 A021501 trial (NCT02839343), which showed that neoadjuvant mFOLFIRINOX provided a favorable overall survival benefit in patients with borderline resectable pancreatic ductal adenocarcinoma when administered prior to pancreatectomy.

Andrew J. Armstrong, MD, MSc, discusses updated data from the phase 3 ARCHES trial (NCT02677896) examining enzalutamide (Xtandi) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, and the clinical implications of the research for this population.

Justin Taylor, MD, discusses the significance of BTK inhibition in patients with chronic lymphocytic leukemia, describes genomic analyses examining resistance mechanisms to the noncovalent BTK inhibitor pirtobrutinib (Jaypirca), and underscores the clinical significance of the data yielded from the research.

Muhammad Bilal Abid, MD, MRCP, highlights the clinical takeaways from a study examining the effectiveness of a third SARS-CoV-2 mRNA vaccine dose among patients treated with hematopoietic cell transplantation, CAR T-cell therapy, and bispecific antibodies.

Sameek Roychowdhury, MD, PhD, contextualizes safety and efficacy data reported from a phase 2 study (NCT02150967) examining infigratinib (Truseltiq) in patients with FGFR2-positive cholangiocarcinoma, describes nuances to treatment with the agent, and sheds light on ongoing research efforts being made to further improve outcomes in this population.

Muhammad Bilal Abid, MD, MRCP, discusses findings from a study outlining what is known about the risk of infections with CAR T-cell therapy and determinants of SARS-CoV-2 responses.

Co-authors Jacob Scott, MD, DPhil, and Javier Torres-Roca, MD, discuss their study, which found that genomic-adjusted radiation dose had a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had received radiation therapy, indicating that genomics should be used to guide dosing decisions.

Chris Labaki, MD, and Quoc-Dien Trinh, MD, shed light on their research detailing a decline in cancer screenings during the height of the COVID-19 pandemic, the recovery of this testing, and existing disparities to be addressed with additional efforts.

Balazs Halmos, MD, discusses findings from a study he participated on, which found that COVID-19 vaccination induced high rates of seroconversion in patients with cancer, although those with hematologic malignancies had lower immunogenicity and those who received prior immunosuppressive therapies appeared to be less responsive.

C. Ola Landgren, MD, PhD, discusses data from the phase 2 MANHATTAN trial, which showed that carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone, and daratumumab (Darzalex) yielded high rates of minimal residual disease negativity in patients with newly diagnosed multiple myeloma.

C.Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their study exploring the utility of whole-genome sequencing in patients with monoclonal gammopathy of uncertain significance and smoldering myeloma to see whether they could identify genomic signatures capable of predicting progression to multiple myeloma.

Sophia George, PhD, and Judith E. Hurley, MD, walk through their study which found that 1 in 7 Caribbean-born adults with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, providing opportunities for targeted therapies and unique preventative approaches.

Ghaith Abu-Zeinah, MD, shares data from a retrospective study which indicated that interferon-alpha significantly improved myelofibrosis-free survival and overall survival over hydroxyurea (Hydrea) and phlebotomy only in patients with polycythemia vera.

Co-authors Toni K. Choueiri, MD and Robert J. Motzer, MD, discuss how data from the phase 3 CheckMate-9ER trial (NCT03121177) confirmed the advantage of frontline cabozantinib (Cabometyx) plus nivolumab (Opdivo) vs sunitinib (Sutent) in terms of survival and responses in patients with advanced renal cell carcinoma.